Optiscan and Mayo Clinic Achieve Major Milestone in Robotic Surgery Imaging Collaboration.

Optiscan Imaging Limited (ASX: OIL) and the Mayo Clinic have successfully advanced the development of a robotic-compatible digital confocal laser endomicroscopic imaging system, following their mid-2024 Know-How Agreement. The collaboration has achieved all targeted 12-month milestones, including prototype development, hardware-software integration, and workflow analysis for robotic-assisted breast cancer surgeries. The innovative system is designed to offer high-resolution, real-time imaging to improve surgical accuracy, tissue classification, and cancer margin detection. Key achievements include compatibility testing with robotic systems, concept validation, and creation of adaptable imaging probe accessories.

The next phase will transition to the Mayo Clinic’s Florida campus, expanding collaborative opportunities. This project aims to redefine precision in robotic surgery, streamline operations, and improve patient outcomes. Optiscan’s CEO, Dr Camile Farah, expressed confidence in the platform’s potential for broader clinical applications, underscoring the partnership's success and transformative impact in medical imaging technology.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com